Erratum: Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor (Cancer Cell (2014) 26(6) (909–922) (S1535610814004231) (10.1016/j.ccell.2014.10.019));Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor

Cancer Cell

Volumn 26, Issue 6, 2014, Pages 909-922

  Christensen, Camilla L ^a   Kwiatkowski, Nicholas ^b   Abraham, Brian J ^b   Carretero, Julian ^c   Al Shahrour, Fatima ^d   Zhang, Tinghu ^e   Chipumuro, Edmond ^e   Herter Sprie, Grit S ^a   Akbay, Esra A ^a   Altabef, Abigail ^a   Zhang, Jianming ^e   Shimamura, Takeshi ^f   Capelletti, Marzia ^a   Reibel, Jakob B ^a   Cavanaugh, Jillian D ^a   Gao, Peng ^a   Liu, Yan ^a   Michaelsen, Signe R ^g   Poulsen, Hans S ^g   Aref, Amir R ^a   Barbie, David A ^a   Bradner, James E ^a   George, Rani E ^e   Gray, Nathanael S ^e   Young, Richard A ^b,h   Wong, Kwok Kin ^a,e   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^c UNIVERSITY OF VALENCIA   (Spain)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f LOYOLA UNIVERSITY CHICAGO   (United States)

^g FINSEN LABORATORY   (Denmark)

^h MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 CHLOROANILINO) 4 [2 (3 HYDROXYPROPYLAMINO) 4 PYRIDYL]PYRIMIDINE; 4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; ALPHA AMINO N [5,6 DIHYDRO 2 (1 METHYL 1H PYRAZOL 4 YL) 6 OXO 1H PYRROLO[4,3,2 EF][2,3]BENZODIAZEPIN 8 YL]CYCLOHEXANEACETAMIDE; ALVESPIMYCIN; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 8; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; DINACICLIB; ETOPOSIDE; FLAVOPIRIDOL; LUMINESPIB; MYC PROTEIN; PIK 75; PROTEIN P53; RIGOSERTIB; THZ 1; TORIN 2; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; XMD 16 144; CYCLIN DEPENDENT KINASE; ENZYME INHIBITOR; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; GENOTYPE; IC50; IN VITRO STUDY; MOUSE; NONHUMAN; SMALL CELL LUNG CANCER; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; DNA SEQUENCE; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; LUNG NEOPLASMS; METABOLISM; MOLECULAR GENETICS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LUNG NEOPLASMS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; SEQUENCE ANALYSIS, DNA; SMALL CELL LUNG CARCINOMA; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919495606     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2014.12.007     Document Type: Erratum

References (43)

1. Ball D.W. Achaete-scute homolog-1 and Notch in lung neuroendocrine development and cancer. Cancer Lett. 2004, 204:159-169.
2. Borges M., Linnoila R.I., van de Velde H.J., Chen H., Nelkin B.D., Mabry M., Baylin S.B., Ball D.W. An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature 1997, 386:852-855.
3. Bösken C.A., Farnung L., Hintermair C., Merzel Schachter M., Vogel-Bachmayr K., Blazek D., Anand K., Fisher R.P., Eick D., Geyer M. The structure and substrate specificity of human Cdk12/Cyclin K. Nat. Commun. 2014, 5:3505.
4. Brennan J., O'Connor T., Makuch R.W., Simmons A.M., Russell E., Linnoila R.I., Phelps R.M., Gazdar A.F., Ihde D.C., Johnson B.E. myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Res. 1991, 51:1708-1712.
5. Carney D.N., Bunn P.A., Gazdar A.F., Pagan J.A., Minna J.D. Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung. Proc. Natl. Acad. Sci. U S A 1981, 78:3185-3189.
6. Chapuy B., McKeown M.R., Lin C.Y., Monti S., Roemer M.G., Qi J., Rahl P.B., Sun H.H., Yeda K.T., Doench J.G., et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013, 24:777-790.
7. Christensen C.L., Gjetting T., Poulsen T.T., Cramer F., Roth J.A., Poulsen H.S. Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer-specific cytotoxicity and tumor growth delay. Clin. Cancer Res. 2010, 16:2308-2319.
8. Dooley A.L., Winslow M.M., Chiang D.Y., Banerji S., Stransky N., Dayton T.L., Snyder E.L., Senna S., Whittaker C.A., Bronson R.T., et al. Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev. 2011, 25:1470-1475.
9. DuPage M., Dooley A.L., Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 2009, 4:1064-1072.
10. Ember S.W., Zhu J.Y., Olesen S.H., Martin M.P., Becker A., Berndt N., Georg G.I., Schonbrunn E. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem. Biol. 2014, 9:1160-1171.
11. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
12. Hnisz D., Abraham B.J., Lee T.I., Lau A., Saint-André V., Sigova A.A., Hoke H.A., Young R.A. Super-enhancers in the control of cell identity and disease. Cell 2013, 155:934-947.
13. Huang M., Weiss W.A. Neuroblastoma and MYCN. Cold Spring Harbor Persp. Med. 2013, 3:a014415.
14. Huijbers I.J., Bin Ali R., Pritchard C., Cozijnsen M., Kwon M.C., Proost N., Song J.Y., de Vries H., Badhai J., Sutherland K., et al. Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. EMBO Mol. Med. 2014, 6:212-225.
15. Ito T., Udaka N., Yazawa T., Okudela K., Hayashi H., Sudo T., Guillemot F., Kageyama R., Kitamura H. Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development 2000, 127:3913-3921.
16. Jiang T., Collins B.J., Jin N., Watkins D.N., Brock M.V., Matsui W., Nelkin B.D., Ball D.W. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res. 2009, 69:845-854.
17. Johnson B.E., Ihde D.C., Makuch R.W., Gazdar A.F., Carney D.N., Oie H., Russell E., Nau M.M., Minna J.D. myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J.Clin. Invest. 1987, 79:1629-1634.
18. Jonkers J., Meuwissen R., van der Gulden H., Peterse H., van der Valk M., Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 2001, 29:418-425.
19. Kim Y.H., Girard L., Giacomini C.P., Wang P., Hernandez-Boussard T., Tibshirani R., Minna J.D., Pollack J.R. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene 2006, 25:130-138.
20. Kwiatkowski N., Zhang T., Rahl P.B., Abraham B.J., Reddy J., Ficarro S.B., Dastur A., Amzallag A., Ramaswamy S., Tesar B., et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 2014, 511:616-620.
21. Lan M.S., Breslin M.B. Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine differentiation. FASEB J. 2009, 23:2024-2033.
22. Lin C.Y., Lovén J., Rahl P.B., Paranal R.M., Burge C.B., Bradner J.E., Lee T.I., Young R.A. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012, 151:56-67.
23. Liu Y., Marks K., Cowley G.S., Carretero J., Liu Q., Nieland T.J., Xu C., Cohoon T.J., Gao P., Zhang Y., et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov. 2013, 3:870-879.
24. Lovén J., Orlando D.A., Sigova A.A., Lin C.Y., Rahl P.B., Burge C.B., Levens D.L., Lee T.I., Young R.A. Revisiting global gene expression analysis. Cell 2012, 151:476-482.
25. Lovén J., Hoke H.A., Lin C.Y., Lau A., Orlando D.A., Vakoc C.R., Bradner J.E., Lee T.I., Young R.A. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
26. McFadden D.G., Papagiannakopoulos T., Taylor-Weiner A., Stewart C., Carter S.L., Cibulskis K., Bhutkar A., McKenna A., Dooley A., Vernon A., et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 2014, 156:1298-1311.
27. Meuwissen R., Linn S.C., Linnoila R.I., Zevenhoven J., Mooi W.J., Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003, 4:181-189.
28. Northcott P.A., Shih D.J., Peacock J., Garzia L., Morrissy A.S., Zichner T., Stütz A.M., Korshunov A., Reimand J., Schumacher S.E., et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012, 488:49-56.
29. Osada H., Tatematsu Y., Yatabe Y., Horio Y., Takahashi T. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res. 2005, 65:10680-10685.
30. Osborne J.K., Larsen J.E., Shields M.D., Gonzales J.X., Shames D.S., Sato M., Kulkarni A., Wistuba I.I., Girard L., Minna J.D., Cobb M.H. NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM. Proc. Natl. Acad. Sci. U S A 2013, 110:6524-6529.
31. Park K.S., Liang M.C., Raiser D.M., Zamponi R., Roach R.R., Curtis S.J., Walton Z., Schaffer B.E., Roake C.M., Zmoos A.F., et al. Characterization of the cell of origin for small cell lung cancer. Cell Cycle 2011, 10:2806-2815.
32. Pedersen N., Mortensen S., Sørensen S.B., Pedersen M.W., Rieneck K., Bovin L.F., Poulsen H.S. Transcriptional gene expression profiling of small cell lung cancer cells. Cancer Res. 2003, 63:1943-1953.
33. Peifer M., Fernández-Cuesta L., Sos M.L., George J., Seidel D., Kasper L.H., Plenker D., Leenders F., Sun R., Zander T., et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 2012, 44:1104-1110.
34. Pleasance E.D., Stephens P.J., O'Meara S., McBride D.J., Meynert A., Jones D., Lin M.L., Beare D., Lau K.W., Greenman C., et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010, 463:184-190.
35. Reynolds S.D., Giangreco A., Power J.H., Stripp B.R. Neuroepithelial bodies of pulmonary airways serve as a reservoir of progenitor cells capable of epithelial regeneration. Am. J. Pathol. 2000, 156:269-278.
36. Rudin C.M., Durinck S., Stawiski E.W., Poirier J.T., Modrusan Z., Shames D.S., Bergbower E.A., Guan Y., Shin J., Guillory J., et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 2012, 44:1111-1116.
37. Sato M., Shames D.S., Gazdar A.F., Minna J.D. A translational view of the molecular pathogenesis of lung cancer. J.Thorac. Oncol. 2007, 2:327-343.
38. Sawarkar R., Sievers C., Paro R. Hsp90 globally targets paused RNA polymerase to regulate gene expression in response to environmental stimuli. Cell 2012, 149:807-818.
39. Sutherland K.D., Proost N., Brouns I., Adriaensen D., Song J.Y., Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011, 19:754-764.
40. Travis W.D. Lung tumours with neuroendocrine differentiation. Eur. J. Cancer 2009, 45(Suppl 1):251-266.
41. Voortman J., Lee J.H., Killian J.K., Suuriniemi M., Wang Y., Lucchi M., Smith W.I., Meltzer P., Wang Y., Giaccone G. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc. Natl. Acad. Sci. U S A 2010, 107:13040-13045.
42. Whyte W.A., Orlando D.A., Hnisz D., Abraham B.J., Lin C.Y., Kagey M.H., Rahl P.B., Lee T.I., Young R.A. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 2013, 153:307-319.
43. William W.N., Glisson B.S. Novel strategies for the treatment of small-cell lung carcinoma. Nat. Rev. Clin. Oncol. 2011, 8:611-619.